Бралангин®

General characteristics. Structure:

Active ingredients: 0,5 g of analginum, 0,002 g of a pitofenon of a hydrochloride, 0,00002 g bromide fenpiveriniya.

Excipients: sodium pyrosulphite, water for injections.

Pharmacological properties:

Pharmacodynamics. Bralangin - the combined drug, has anesthetic, febrifugal and spasmolytic effect.

Metamizol is derivative pyrazyl ketone. Possesses soothing, febrifugal and weak antiinflammatory action. Pitofenon, like a papaverine, has direct myotropic effect on smooth muscles of internals and causes its relaxation. Fenpiveriny due to holinoblokiruyushchy action makes the additional weakening impact on smooth muscles.

The combination of three components of drug strengthens their pharmacological action which is expressed in pain relief, relaxation of unstriated muscles, decrease to the increased body temperature.

Indications to use:

Pain syndrome at spasms of smooth muscles of internals - renal and bilious gripes, enterospasms, a dysmenorrhea and other spastic conditions of internals. It can be used for a short-term symptomatic treatment at joint pains, neuralgia, an ischialgia, a mialgiya. As supportive application can be applied to reduction of pains after surgical and diagnostic interventions.

If necessary drug can be used for decrease in the increased body temperature at catarrhal and infectious and inflammatory diseases.

Route of administration and doses:

The single dose for adults and teenagers is more senior than 15 years makes 2-5 ml (intravenously or intramusculary), a daily dose - to 10 ml. Intravenous administration of the single dose exceeding 2 ml is possible only after careful specification of indications.

For children and chest babies the daily dose is established taking into account body weight.

• Chest babies of 5-8 kg, 3-11 months: intravenous administration is contraindicated, intramusculary 0,1-0,2 ml;
• Children of 9-15 kg, 1 - 2 years: intravenously 0,1-0,2 ml, intramusculary 0,2-0,3 ml;
• Children of 16-23 kg, 3-4 years: intravenously 0,2-0,3 ml, intramusculary 0,3-0,4 ml;
• Children of 24-30 kg, 5-7 years: intravenously 0,3-0,4 ml, intramusculary 0,4-0,5 ml;
• Children of 31 - 45 kg, 8-12 years: intravenously 0,5-0,6 ml, intramusculary 0,6-0,7 ml;
• Children of 46-53 kg, 12-15 years: intravenously 0,8-1,0 ml, intramusculary 0,8-1,0 ml.

It is necessary to carry out intravenous administration of drug slowly (on 1 ml within, at least, 1 min.), in position of the patient lying also under control of arterial pressure, frequency of reductions of heart and breath. Injection solution has to have body temperature.

Solution is incompatible in one syringe with any other medicines. Side effect

In therapeutic doses drug is usually well transferred. Allergic reactions are sometimes possible (skin rash, an itch, it is very rare - an acute anaphylaxis, Stephens-Johnson and Layell's syndromes). In isolated cases - burning sensation in epigastric area, dryness in a mouth, a headache.

Dizziness, lowering of arterial pressure, tachycardia, cyanosis are possible. At long reception - hemopoiesis disturbance cases (thrombocytopenia, a granulocytopenia, an agranulocytosis, a hemorrhage). At tendency to a bronchospasm provoking of an attack is possible.

Features of use:

Use during pregnancy and a lactation is contraindicated.

Side effects:

It is not described.

Interaction with other medicines:

Simultaneous use of Bralangina® with other non-narcotic analgesics can lead to mutual strengthening of toxic effects.

Tricyclic antidepressants, contraceptives for intake, Allopyrinolum increase toxicity of drug.

Barbiturates, phenylbutazone and drgy inductors of microsomal enzymes of a liver weaken effect of metamizol.

Simultaneous use with cyclosporine reduces the level of the last in blood.

Sedatives and tranquilizers strengthen the anesthetizing action of a bralangin.

In need of simultaneous use of the specified and other medicines it is necessary to consult with the doctor.

At long use of drug (more than a week) control of a picture of peripheral blood and a functional condition of a liver is necessary.

Drug is used at adults by no more than 5 days; children have no more than 3 days. More prolonged use is possible only after consultation with the doctor.

Contraindications:

- hypersensitivity to pyrazyl ketone derivatives (Butadionum, Tribuzonum), to other components of drug,

- the expressed abnormal liver functions and kidneys,

- genetic absence glyukozo-6-fosfatdegidrogenazy,

- tachyarrhythmia,

- closed-angle form of glaucoma,

- a prostatauxe with a tendency to an ischuria,

- gastrointestinal impassability and megacolon,

- bronchial asthma,

- diseases of system of blood,

- kollaptoidny states.

- the first trimester and last 6 weeks of pregnancy,

- lactation period,

- the early children's age (up to 3 months) or body weight is less than 5 kg.

With care and under control of the doctor patients should use drug with the broken function of a liver or kidneys, at tendency to hypotonia, a bronchospasm, and also at the increased individual sensitivity to non-steroidal anti-inflammatory drugs or non-narcotic analgesics. Metabolites of metamizol can sometimes paint urine in red color. During treatment by drug not to accept alcohol.

Overdose:

At overdose the following symptoms can be observed by drug: vomiting, feeling of dryness in a mouth, sweating change, accommodation disturbance, arterial hypotension, drowsiness, confusion of consciousness, an abnormal liver function and kidneys, a spasm.

Treatment - symptomatic.

Storage conditions:

To store in the dry, protected from light place at a temperature not above +25 °C. To store in the place, unavailable to children. A period of validity - 3 years. Not to use upon termination of the period of validity specified on packaging.

Issue conditions:

According to the recipe

Packaging:

On 5 ml in ampoules. In packaging of 5 or 10 ampoules. Packaging: ampoules of dark glass (5)/complete with a knife ampoule or the scarificator/-упаковки cell planimetric ampoules of dark glass (5) - planimetric strip packagings.